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Abstract
Background: Gastric cancer is one of the common cancers seen in south India. Unfortunately more than 90% are
advanced by the time they report to a tertiary centre in the country. There is an urgent need to characterize these
cancers and try to identify potential biomarkers and novel therapeutic targets.
Materials and methods: We used 24 gastric cancers, 20 Paired normal (PN) and 5 apparently normal gastric
tissues obtained from patients with non-gastric cancers (Apparently normal - AN) for the microarray study followed
by validation of the significant genes (n = 63) by relative quantitation using Taqman Low Density Array Real Time
PCR. We then used a custom made Quantibody protein array to validate the expression of 15 proteins in gastric
tissues (4 AN, 9 PN and 9 gastric cancers). The same array format was used to study the plasma levels of these
proteins in 58 patients with gastric cancers and 18 from patients with normal/non-malignant gastric conditions.
Results: Seventeen genes (ASPN, CCL15/MIP-1δ, MMP3, SPON2, PRSS2, CCL3, TMEPAI/PMEPAI, SIX3, MFNG,
SOSTDC1, SGNE1, SST, IGHA1, AKR1B10, FCGBP, ATP4B, NCAPH2) were shown to be differentially expressed
between the tumours and the paired normal, for the first time. EpCAM (p = 0.0001), IL8 (p = 0.0003), CCL4/MIP-1b
(p = 0.0026), CCL20/MIP-3a (p = 0.039) and TIMP1 (p = 0.0017) tissue protein levels were significantly different
(Mann Whitney U test) between tumours versus AN & PN. In addition, median plasma levels of IL8, CXCL9/MIG,
CCL3/MIP-1a, CCL20/MIP-3a, PDGFR-B and TIMP1 proteins were significantly different between the non-malignant
group and the gastric cancer group. The post-surgical levels of EpCAM, IGFBP3, IL8, CXCL10/IP10, CXCL9/MIG,
CCL3/MIP-1a, CCL20/MIP-3a, SPP1/OPN and PDGFR-B showed a uniform drop in all the samples studied.
Conclusions: Our study has identified several genes differentially expressed in gastric cancers, some for the first
time. Some of these have been confirmed at the protein level, as well. Some of these proteins will need to be
evaluated further for their potential as diagnostic biomarkers in gastric cancers and some could be useful as
follow-up markers in gastric cancer.
Introduction
Gastric cancer is one of the common cancers seen in
South India, ranked 2nd among men and 5th among
women in the Chennai Metropolitan area [1]. Of the
patients presenting to the tertiary Institution, more than
90% are advanced at presentation and only palliative
management is feasible in these patients [2]. In 2005
and 2006, a total of 1239 gastric cancer patients were
seen at the Institute, of which 211 patients had been
previously treated elsewhere. Among the treatment
naïve patients (n = 1028), 61% were locally advanced
and 39% were with distant metastasis. In view of the
advanced nature of the disease and due to poor perfor-
mance status, only 91 patients came up for surgery with
intent to cure. This highlights the problem of lack of
early detection for the gastric cancer in India.
In Japan, which has a high incidence of gastric cancer,
photofluorography screening is done as a screening pro-
gram for the population, resulting in early detection of
lesions, some confined to mucosa only [3]. Such a pro-
cedure is unlikely to be the solution in a large country
such as India. In view of the subtle symptoms such as
indigestion, gradual weight loss which are generally
ignored, most patients present with advanced disease.
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It is therefore essential to develop reliable screening
tests which can help in early detection of the disease.
Serum based tests for Pepsinogen and H. pylori antibody
have not gained widespread acceptance and have not
been considered for screening individuals by the
National Cancer Center, Tokyo, Japan [3]. The diagnos-
tic test should be preferably blood or urine sample
based and needs to be specific.
Among the major risk factors for gastric cancer, diet
plays an important role. Consumption of salted food (fish
and meat) and tobacco are associated with an increased
risk [4-6]. Chronic atrophic gastritis and intestinal meta-
plasia have been considered as pre-malignant changes in
the gastric mucosa. Tobacco smoking, H. pylori, diets
with high content of salt, nitrites and nitrates, and low
intake of fruits and vegetables are known risk factors for
chronic atrophic gastritis [7]. The south Indian diet tradi-
tionally consists of high chilly content and deep fried
food, with the oil used for frying undergoing several
cycles of usage before being discarded and hence contain-
ing a high content of carcinogens [5,8,9].
Gastric cancers are predominantly adenocarcinomas
and could be of three sub-types - Intestinal, Diffuse and
Mixed [10]. The Intestinal type of gastric cancer is
usually seen in the distal part of stomach, has precan-
cerous stages and comprises of cohesive cancer cells
forming gland like structures [11]. Most of the intestinal
types are well to moderately differentiated (WHO Clas-
sification). The Diffuse type consists of individual cancer
cells infiltrating and spreading far beyond its macro-
scopic borders. They are usually poorly differentiated to
undifferentiated [12]. In Chennai, distal tumours are
more common than proximal cancers.
Gene expression studies in different cancers have
helped in identifying genes involved in the process of
tumorigenesis [13]. Microarray studies comparing the
gene expression differences between normal stomach
and gastric cancer [14], between young and elderly gas-
tric cancer patients’ tumours [15], between primary
tumour and metastatic lesions [16] have been reported.
Our study compares the gene expression between appar-
ently normal gastric tissues obtained from patients with
non-gastric cancers (Apparently normal - AN), gastric
tissue samples well away from the tumor and confirmed
by frozen section not to have tumour cells (Paired nor-
mal - PN) and gastric cancers (Tumours - T). This is
the first study to look into the gene expression patterns
of gastric cancers in south Indian patients and validate
some of these genes at the protein level for their poten-
tial as biomarkers for gastric cancer.
Materials and methods
Five AN samples (2 from patients with Hypopharyngeal
cancer, 1 from upper oesophageal squamous cell
carcinoma, 1 from peri-ampullary carcinoma, 1 from
pancreatic cancer) from patients who underwent sto-
mach resection as part of their primary surgery were
included in the study. In addition, 24 gastric cancers
and 20 PN were included in the study. All the patients
provided their informed consent for the study, which
was approved by the Institutional Ethical committee.
The operative specimens were immediately processed
and sections were taken for frozen section. Tumour
samples with more than 70% cancer cells; PN and AN
samples with no evidence of tumour cells and appar-
ently normal morphology were included in the study.
In addition, blood samples were collected from indivi-
duals undergoing oesophagogastroduodenoscopy (OGD-
scopy) for dyspeptic symptoms and to rule out any
upper gastrointestinal tract pathology. Of this, 58 were
found to be gastric cancers, 6 were found to have
benign pathology in the stomach (gastritis, benign ulcer)
and 12 had a normal OGDscopy report. In 8 gastric
cancer patients who underwent radical surgery, post-
operative blood sample was also collected between day 7
and day 15 except two patients in whom the sample was
collected at the time of their first follow-up after surgery
(days 55 and 64).
RNA extraction
The RNA was extracted from the tissue samples using
the RNeasy RNA extraction kit (Qiagen, Gmbh, Hilden;
Cat no: 74106) as per the manufacturer’s instructions.
The quality of the RNA used for micro-array analysis
was checked using the Bioanalyzer and samples with a
RNA Integrity Number (RIN) of 7 or more were
included in the study. RNA was quantitated using Nano-
Drop™ ND1000 (NanoDrop Technologies, USA)
spectrophotometer.
Detection of H pylori
Analysis for H pylori in gastric tissue samples was per-
formed using PCR as previously described [17]. PCR
primers designed to amplify S2 region of Vac A gene
in the H pylori genome were used for detection. The
reaction amplifies an amplicon of approximately 194
bp length.
Microarray experiment
1 μg of total RNA from the tumour/PN/AN sample and
universal RNA (Stratagene; Cat no: 740000-41) were
reverse transcribed using Array script at 42°C for 2 hrs
to obtain cDNA using the Amino Allyl MessageAmp II
aRNA amplification kit (Ambion, Austin, Tx; Cat no:
AM1797). The cDNA was amplified, labelled, hybridized
and slides scanned as described earlier [18].
All the raw data files have been submitted to GEO
with an assigned GEO accession number - GSE17154.
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Microarray data analysis
The Foreground and Background Median intensity for
Cy3 and Cy5, were imported into BRB-ArrayTools soft-
ware [19] using the Import wizard function. Background
correction was not done. Global normalization was used
to median centre the log-ratios on each array in order to
adjust for differences in labelling intensities of the Cy3
and Cy5 dyes. The data was analysed using the Class
comparison module [20] in the BRB-ArrayTools software.
Class Comparison in BRB-Array Tools
We identified genes that were differentially expressed
among the 3 classes (tumour/PN/AN) using the Class
Comparison module. Univariate F-test was used and the
genes were considered statistically significant if their
p value was < 0.001. In addition a two fold difference
was required between the different classes.
Quantitative Real time PCR
Real time validation of the gene expression was done
using the TLDA real time PCR (Applied Biosystems,
Foster City, CA; Cat no: 4342261). Triplicate cDNA
template samples were amplified and analysed on the
ABI Prism 7900HT sequence detection system (Applied
Biosystems, Foster City, CA) as described earlier [18].
The raw data from the Prism 7900HT sequence detec-
tion system was imported into Microsoft Excel software
for statistical analysis of the data. Among the endogen-
ous reference genes included on the array (18S riboso-
mal gene; ACTB), ACTB was chosen after visualizing
the global Ct value distribution, for normalizing the
data. In addition, HSPE1 which had been included
based on the differential expression seen on Microarray,
was found to have minimal variation and hence was
included as an additional endogenous control. The
TLDA assays were run at LabIndia Instruments Pvt Ltd
laboratories at Gurgaon, New Delhi.
The AN samples were used as calibrators and the rela-
tive quantitation values were calculated for all the genes
and the samples.
Gene Ontology Analysis
The genes found to be differentially expressed in
tumours and paired normals’ based on the microarray
data were imported into the Fatigo module of Babelo-
mics [21] and analysed for over-representation of the
GO terms in comparison to the rest of the genome,
using Fisher’s exact test for 2 × 2 contingency tables.
The p value was set at < 0.05.
Preparation of Tissue protein lysates and Collection of
Plasma
Protein lysates for analysis using antibody arrays were
prepared from 60-80 mg of frozen gastric tissue
samples. The tissue samples were ground in the pre-
sence of liquid nitrogen using mortar and pestle. The
powdered tissue was re-suspended in tissue lysis buffer
(Tris. HCL pH7.5, 150 mM Sodium chloride, 1%
Sodium deoxycholate, 1%NP40). Prior to use, lysis buffer
was supplemented with Complete mini™ protease inhibi-
tor cocktail (Roche Diagnostics GMBH, Germany). The
protein lysates were subjected to sonication using Vibra
cell™ (Sonics Inc., USA) sonicator. The lysates were
cleared by centrifugation and quantitated using Coomas-
sie Plus-Bradford assay™ reagent (Pierce Inc., USA) as
per manufacturer’s protocol. The quality of the proteins
was analysed by resolving 50 μg of the lysate on 10%
sodium dodecyl sulfate polyacrylamide (SDS) gel and
subsequently visualized by staining using Coomassie
Blue.
Plasma was obtained from 5 ml of blood collected in
the presence of 200 μl of 10% ethylene diamine tetra
acetic acid (EDTA). The plasma isolated from the blood
samples was centrifuged at 3000 g and stored at -80°C
in aliquots.
Antibody Arrays
Custom antibody arrays Quantibody™ array (Catalogue
number: QAA-CUST) based on a multiplex ELISA sys-
tem for quantitative measurement of multiple proteins
purchased from Ray Biotech, Inc, USA was used to
study protein expression levels in gastric tissues and
plasma samples [22,23]. The following genes (CXCL5/
ENA-78, CXCL8/IL8, CXCL10/IP10, CXCL9/MIG,
CCL3/MIP-1a, CCL15/MIP-1δ, EpCAM, MMP3, SPP1/
OPN, TIMP1, Adipsin/CFD, CCL4/MIP-1b, CCL20/
MIP-3a, PDGFR-B and IGFBP-3) found to be overex-
pressed in gastric cancers relative to PN and AN (with
the exception of CFD/Adipsin which was overexpressed
in PN relative to gastric cancers and AN) were studied
for their protein levels in tumour, corresponding PN
and in AN tissues. In addition, plasma levels of these
proteins in patients who had undergone OGDscopy
were estimated using the same array format (58 gastric
cancer patients, 6 with benign gastric or duodenal ulcer
or gastritis and 12 with normal OGDscopy report). In 8
gastric cancer patients who had undergone radical sur-
gery, pre and post-operative samples were collected and
analyzed.
The assay was performed as described by the manu-
facturer’s protocol. Briefly, in the case of the tissue
lysates 100 μg of the protein lysate was prepared by
diluting the tissue lysate stock solution using sample
diluent buffer supplied by the manufacturer to a final
concentration of 1 mg/ml. 100 μl of the diluted lysate
was incubated in the array chamber for 2 hours. In the
case of the plasma samples, the plasma was diluted with
sample diluent buffer supplied with the kit at a ratio of
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1:1. 100 μl of the diluted plasma sample was incubated
in the array chamber for 2 hours. For every array experi-
ment, standards supplied along with the kit were freshly
prepared as described by the manufacturers protocol
and included along with a sample diluent buffer control
(negative control) which neither had standard or sam-
ples. The arrays were processed as described by the
manufacturer’s protocol. The slides were scanned at 5 μ
resolution and a PMT of 70 using Pro Scan Array™ (Per-
kin Elmer Inc., USA). At these scanner settings the sig-
nals from the highest standard concentration did not
reach saturation. The data was analyzed using the
Quantibody Q-Analyzer, an array specific, Microsoft
Excel based program, supplied with the custom arrays.
Statistical analysis
The median and range for the plasma values were calcu-
lated using Microsoft Excel ™ spread sheet software
(Microsoft, Inc.,). Mann Whitney U test (http://faculty.
vassar.edu/lowry/utest.html) was used to study the sig-
nificance of the median values of the plasma and two
tailed test was used for obtaining the p value.
Results
The clinico-pathological details of all the patients, whose
samples were used for the microarray analysis and their
tumour samples, are given in Additional File 1 and 2.
The clinico-pathologic details of the patients from
whom blood samples were obtained for estimation of
the plasma levels of cytokines/chemokines/growth fac-
tors is given in Additional File 3.
Of the 24 patients whose tumour samples were used
for microarray study, 16 were aged more than 45 years
of age and 8 were 45 years or less; 18 were males and 6
were females; 5 were tumours arising in the region of
cardia, 2 from body and 17 from antrum. All the
twenty-four tumours were adenocarcinomas with one of
them being poorly differentiated adenocarcinoma with
areas of neuro-endocrine features. Among the adenocar-
cinomas, Intestinal subtype was the most common (n =
16), while diffuse subtype was seen in 5 and mixed in 2.
Grade III tumours predominated (n = 20), with no
Grade I tumours in our series. Seventeen of 24 were
node positive and 4 had distant metastasis at
presentation.
Based on the Class Comparison analysis (p value =
0.001 and 2 fold difference), we had 61 genes overex-
pressed in cancer, 66 in paired normal and 61 with a
p value of <1e-07 in apparently normal (Additional File
4). We used Taqman Relative Quantitation RT-PCR for
validation of some of the genes identified by the micro-
array analysis. ACTB was chosen as an endogenous con-
trol, which was in addition to the 18S control present in
the TLDA card.
All the 49 samples worked in the TLDA assay but 2
genes, C11orf42 and IGLL1 had not worked. HSPE
which had been found to have differential expression in
the samples in our microarray analysis did not show any
variation in the levels, in the TLDA assay and was
included as an additional endogenous control. Normali-
zation was done using ACTB and HSPE as endogenous
controls. Of the 63 genes selected, excluding the endo-
genous controls (ACTB and HSPE) and the two genes
which had not worked, we had 59 genes for further
analysis.
Three of the genes (REG4, CLDN18, MXRA5) had
been included for validation of their potential as prog-
nostic marker for failure. However, in the interval
between the time that the microarray analysis was com-
pleted and the RQ-RT-PCR analysis was done (approxi-
mately 3 months) there were additional patients who
relapsed and hence the genes were not considered for
further analysis as prognostic markers. However, they
were included to assess whether they were differentially
expressed between PN and tumours.
The list of genes which were identified to be differen-
tially expressed in gastric cancers are given in Table 1
and Table 2. Table 1 lists the genes identified to be dif-
ferentially expressed in gastric cancer for the first time
and Table 2, lists the genes which have been known to
be associated with gastric cancer, and found also in our
study. (Additional Files 5 and 6 provide information on
these genes and the corresponding references). There
are four different patterns of gene expression - Pattern
1 - overexpressed in PN and in Tumours; Pattern 2 -
overexpressed in PN but downregulated in tumours;
Pattern 3 - minimal change in PN but overexpressed in
Tumours and Pattern 4 - minimal change in PN but
downregulated in Tumours (Figure 1).
We then proceeded to confirm the protein expression
for some of the genes in the AN (n = 4), PN (n = 9)
and tumours (n = 9). We used the Quantibody array,
which is based on the principle of sandwich ELISA to
determine the protein levels of 15 cytokines, chemokines
and growth factors [22,23]. The Median values and the
Range of the levels are given in Table 3. CFD/Adipsin
median levels were found to be lower in tumours com-
pared to the levels in PN and AN (p = 0.0324), while
CXCL5/ENA78, CCL20/MIP-3a, IGFBP3, SPP1/OPN
and TIMP1 were increased in PN and tumours relative
to AN, with higher levels seen in tumours. In contrast,
EpCAM, IL8, CXCL10/IP10, CCL3/MIP-1a, CCL4/MIP-
1b, CCL15/MIP-1δ, PDGFR-B were predominantly ele-
vated in tumours compared to AN and PN. EpCAM
(p = 0.0001), IL8 (p = 0.0003), MIP-1b (p = 0.0026),
MIP-3a (p = 0.039) and TIMP1 (p = 0.0017) levels were
significantly different (Mann Whitney U test) between
tumours versus AN & PN. Additionally, EpCAM
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(p = 0.0004), IL8 (p = 0.0015) and MIP-1b (p = 0.0061)
were significantly elevated in tumours compared to their
corresponding PN.
The plasma levels of the 15 cytokines/chemokines/
growth factors were estimated using the Quantibody
array. The 18 non-malignant cases (12 with no abnorm-
ality detected by OGDscopy and 6 with benign pathol-
ogy in the stomach) were clubbed together and the
median values were compared between the tumours and
the non-malignant group. Mann Whitney U test was
performed to assess the statistical significance (two
tailed test). IL8, CXCL9/MIG, CCL3/MIP-1a, CCL20/
MIP-3a, PDGFR-B and TIMP1 plasma levels were sig-
nificantly different between the non-malignant group
and the gastric cancer group (Table 4). SPP1/OPN level
were also higher in gastric cancer patients compared to
the non-malignant group but was borderline significant
(p = 0.05). The post-surgical levels of EpCAM, IGFBP3,
IL8, CXCL10/IP10, CXCL9/MIG, CCL3/MIP-1a,
CCL20/MIP-3a, SPP1/OPN and PDGFR-B showed a
uniform drop in all the 8 samples studied. In contrast
TIMP1, CCL15/MIP-1δ and CFD/Adipsin levels actually
increased in the post-operative period in most of the
samples (Figure 2).
The plasma levels of the cytokines/chemokines/growth
factors were then correlated with the clinico-pathologic
features. 28 of the 58 gastric cancer patients had under-
gone a potentially curative radical surgery (R0 resection)
and 6 patients underwent R1 resection only. These 34
pathologic specimens were available for pathologic
correlations (pT, pN, pStage, perinodal spread, lympha-
tic emboli, vascular emboli), while survival analysis was
done on 28 patients who had undergone a R0 resection.
Ten patients underwent palliative surgical procedures
while 13 patients declined surgery or were unfit for any
intervention other than supportive care. One patient
had an undifferentiated cancer, which on additional
Immunohistochemical studies was found to be a pri-
mary gastric lymphoma, diffuse large B cell type. Plasma
levels for MMP3 where higher in males compared to
females (Median value 16772.1 pg/ml versus 8512.5 pg/
ml) (p value = 0.011); patients with tumours in the car-
dia were found to have higher plasma levels of MIG
compared to other sites [antrum, pylorus and body]
(Median value of 18203.9 pg/ml versus 7204.1 pg/ml)
(p value = 0.032); TIMP1 levels were higher in tumours
arising from the antrum and pylorus compared to those
arising from the body and cardia of the stomach (Med-
ian value 125639.5 pg/ml versus 90820 pg/ml) (p value
= 0.026); IP10, MMP3 and MIP-3a plasma levels were
higher in patients with tumours which had lymphatic
emboli compared to those which were negative (Median
values of 1691.4, 17761.2, 2103.8 versus 543.8, 8359.2,
250.7 pg/ml, respectively) (p value 0.009, 0.009, 0.018,
respectively). Plasma level of MMP3 was also associated
with vascular emboli but this did not achieve statistical
significance. The plasma levels of the cytokines were not
significantly associated with disease-free or overall survi-
val in the 28 patients who underwent radical curative
surgery.
Table 1 Genes reported to be differentially expressed for the first time in gastric cancer [References and details in
Additional File 4]
SNO GENE SYMBOL UPREGULATION REPORTED IN REFERENCE
1 CCL15/MIP5/MIP-1d/LKN1 NSCLC [SF5-R1]
2 ASPN breast cancer [SF5-R2]
3 MMP3 colorectal cancer [SF5-R3]
4 SPON2 Lung, ovarian, prostate cancers [SF5-R4]
[SF5-R5]
[SF5-R6]
5 PRSS22 ovarian cancer [SF5-R7]
6 CCL3/MIP 1A oral SCC [SF5-R8]
7 TMEPAI/PMEPAI Neuro-endocrine tumours [SF5-R9]
8 SIX3
9 MFNG Downregulated in cervical cancer [SF5-R10]
10 SGNE1/SCG5 endocrine tumors
11 SOSTDC1 Downregulated in renal cancer [SF5-R11]
12 SST Downregulated in oesophageal adenocarcinoma [SF5-R12]
13 IGHA1
14 AKR1B10 Increased in Barrett’s epithelium [SF5-R13]
15 FCGBP Down regulated in colon ca [SF5-R14]
16 ATP4B
17 NCAPH2
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Discussion
This is the first gene expression study on gastric cancer
from south India, which has a high incidence rate for
gastric cancers in India. As discussed earlier, diet related
factors play an important role in the pathogenesis of
these cancers [4-6,8,9].
In this study we have compared the gene expression
profile of apparently normal (gastric tissue obtained
from patients undergoing gastric resection for Non-gas-
tric cancers), paired normal (gastric tissue well away
from the gastric tumour and confirmed not to have any
tumour cells) and the gastric tumours. Most studies
have used the paired normal and the tumour for study-
ing the gene expression patterns [14,24,25] while others
have compared biopsies from erosive gastritis, atrophic
gastritis, intestinal metaplasia and gastric cancers [26].
A few studies have used Laser capture micro-dissection
to profile the gastric cancer cells [27].
Our study has identified for the first time several
genes (n = 17) as being differentially expressed in gastric
cancers (Table 1). In addition, 33 genes known to have
been involved in gastric cancer were confirmed in our
study as well (Table 2). Additional Files (5 and 6) indi-
cate the known function of the genes obtained from
Gene Cards [28].
Our study identified a large number of genes asso-
ciated with the extracellular matrix (SPARC, SER-
PINH1/HSP47, COL1A1, COL1A2, COL4A1, MMP3,
TIMP1, PRSS2, CDH3, SPP1, IL8, CTSB, LUM, CEA-
CAM, CTHRC1, SULF1, ASPN, SPON2 and CLDN18)
and chemokine activity, to be differentially expressed in
gastric cancers.
Table 2 Genes known to be involved in gastric cancer tumorigenesis identified in this study [References and details in
Additional File 5]
S NO GENE SYMBOL UP OR DOWN REGULATED REFERENCE
1 CTSB Up-regulated especially in cardia tumours [SF6-R1]
2 SPARC/Osteonectin Up-regulated [SF6-R2]
3 COL1A1 Up-regulated [SF5-R3]
4 COL1A2 Up-regulated [SF5-R3]
5 COL4A1/Arresten Up-regulated [SF5-R4]
6 CXCL1/GRO1/MGSA Up-regulated [SF5-R5]
7 SPP1/osteopontin Up-regulated [SF5-R6]
8 CXCL9/MIG Up-regulated [SF5-R7]
9 IL8/CXCL8 Up-regulated [SF5-R8]
10 TIMP1 Up-regulated [SF5-R9]
11 LUM/SLRR2D/LDC Up-regulated [SF5-R10]
12 CXCL5/ENA78 Up-regulated [SF5-R11]
13 CXCL10/INP10/IP10 Up-regulated [SF5-R4]
14 CEACAM6 Up-regulated [SF5-R12]
15 REGIV Up-regulated [SF5-R13]
16 S100A10/ANX2L/CAL1L Up-regulated [SF5-R14]
17 SERPINH1/HSP47/CBP1 Up-regulated [SF5-R15]
18 CDH3 Up-regulated [SF5-R16
19 TACSTD1/EPCAM/CD326 Up-regulated [SF5-R17]
20 IFITM1/LEU13 Up-regulated [SF5-R18]
21 CTHRC1 Up-regulated [SF5-R19]
22 SULF1 Up-regulated [SF5-R20]
23 RNASE1 Down-regulated [SF5-R21]
24 PGC Down-regulated [SF5-R22]
25 PGA5 Down-regulated [SF5-R22]
26 GIF Down-regulated [SF5-R23]
27 LTF Down-regulated [SF5-R24]
28 TFF1 Down-regulated [SF5-R25]
29 CLDN18 Down-regulated [SF5-R26]
30 CFD/Adipsin Secreted by gastric ca cell lines [SF5-R27]
31 GHRL/Obestatin Down-regulated [SF5-R28]
32 LIPF Down-regulated [SF5-R29]
33 ANXA10 Down-regulated [SF5-R30]
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SPARC, SERPINH1 and CTHRC1 are involved in col-
lagen synthesis; while MMP3, CTSB are involved in
breakdown of extracellular matrix, and TIMP could
inhibit MMP activity. PRSS2 converts inactive MMP3
into active MMP3 while SPARC can activate MMP2.
TIMP has additional tumour promoting role in onco-
genesis, stimulating proliferation [29] and inhibiting
apoptosis [30,31] thereby contributing to the malignant
phenotype. ASPN, an extracellular matrix protein, which
inhibits TGF-b and BMP2, is overexpressed in the gas-
tric cancers relative to the paired normal [32].
REG4 has been reported to be a marker for peritoneal
metastasis in gastric cancer [33] and this was supported
by our study which showed that REG4 overexpression is
associated with metastatic disease. SERPINH1 (HSP47)
was also associated with metastatic disease and had
been shown earlier to be a marker for metastatic
tumour cells [34].
Some of the tumour suppressor genes identified in our
study included Lactotransferrin (LTF), MFNG and
SOSTDC1. LTF has been found to inhibit invasiveness
of the gastrointestinal tumour cell lines [35]. MFNG has
been shown to inhibit Jagged-Notch signalling in cervi-
cal cancer cells. Introduction of MFNG into the CaSki
cervical cancer cell line leads to inhibition of its tumori-
genicity [36].
Several cytokine mRNAs’ (CCL3/MIP-1a, CCL15/
MIP-1δ, CXCL1, CXCL5/ENA78, CXCL8/IL8, CXCL9/
MIG, CXCL10/IP10) were found to be overexpressed in
the tumours while CCL15/MIP-1δ, CXCL5/ENA78 and
IL8 mRNAs’ were overexpressed in paired normals, as
well. However, at the protein level, there was up-regula-
tion of CXCL5/ENA78, CCL20/MIP3-a, IGFBP3, OPN
and TIMP1 in tumours and their PN, indicating that
these could be early events in the gastric tumorigenesis.
Park et al., (2007) [37] had reported CXCL5/ENA78
overexpression to be associated with late stage gastric
cancer and nodal metastasis, using immunohistochemis-
try (IHC). Our study, using a more sensitive assay, sug-
gests CXCL5/ENA78 to be involved in early phases of
Figure 1 RQ values of Paired normals (PN) (n = 20) and Tumour (n = 24), using apparently normal (AN) (n = 5) as calibrator. The fold
change is relative to the apparently normals.
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tumourigenesis as well. Interestingly, CXCL5/ENA78
was found to induce a proliferative response in non-
transformed prostate cell lines [38]. CCL20/MIP-3a has
been known to be expressed in inflamed gastric tissue
and plays a role in H.pylori induced gastritis [39]. Using
IHC, IGFBP3 was found to be overexpressed in gastric
cancers relative to the normal gastric tissue [40]. SPP1/
OPN has also been reported to be overexpressed in gas-
tric cancers and increasing levels have been detected
with progression of disease [41]. TIMP1 is an inhibitor
of matrix metalloproteinases but at the same time can
also induce cell proliferation and has an anti-apoptotic
effect. It has been reported to be overexpressed in gas-
tric cancer cells and in the inflammatory cells of the
stromal element of the tumour [42].
EpCAM, IL8, CXCL10/IP10, CCL3/MIP-1a, CCL4/
MIP-1b, CCL15/MIP-1δ, PDGFR-B protein were found
to be expressed predominantly in tumours only,
Table 3 Median values for cytokines and chemokines in an, pn and tumour lysates
AN AN PN PN TUMOUR TUMOUR
Median in pg/ml Range in pg/ml Median in pg/ml Range in pg/ml Median in pg/ml Range in pg/ml
CFD/Adipsin 27295.0 22097.9-31759.9 27162.9 19515.1 - 38224.3 13021.0* 9441.5 - 36873.1
CXCL5/ENA-78 283.8 39.3-4206.1 2922.7 84.9 - 31628.7 3978.0 723.9 - 40669.6
EpCAM 1466.0 905.7-2266.6 2243.5 915 - 8885.8 18717.6***/### 8966.1 - 34529
IGFBP-3 3149.8 124.0 - 17530.2 12286.0 134.6 - 34036.3 17662.7 196.9 - 55671.5
IL-8/CXCL8 22.1 0 - 62.3 53.1 27.4 - 190.6 1240.4***/### 93.1 - 3660.7
CXCL10/IP-10 20.4 1.4 - 146.1 147.0 0.8 - 3940.9 384.4 0.7 - 1643.1
CXCL9/MIG 369.5 0 - 8569.7 4336.1 1077.2 - 19396.6 7540.3 727.7 - 73975.9
CCL3/MIP-1a 0.0 0 - 187.4 203.6 0 - 1177.2 359.0 0 - 3231.5
CCL4/MIP-1b 49.5 0 - 261.8 94.3 0 - 335.8 578.6**/# 28.7 - 1185.2
CCL15/MIP-1δ 86.0 54 - 157.3 169.3 51.7 - 748.9 374.3 63.4 - 2825.4
CCL20/MIP-3a 859.3 76.1-1784.8 3049.6 893 - 16262.9 4773.4* 1014.4 - 13280.7
MMP-3 269.0 0 - 648.6 143.9 0 - 353.1 0.0 0 - 2908.2
SPP1/OPN 447.0 9.1 - 896.3 2054.0 193.6 - 3183.7 1407.1 12.6 - 5819.2
PDGF R-B 222.3 174.3 - 521.4 295.3 184.9 - 1079.3 578.6 123.7 - 1516.8
TIMP-1 9676.2 4373.3 - 17133.2 27022.2 17028.3 - 194387.8 139365.6** 48146.4 - 367203.2
AN - Apparently normal; PN - Paired normal
p value significant for AN+PN versus Tumour -
* - <0.05; ** - <0.005; *** - <0.0005 by Mann Whitney U test.
p value significant for PN versus Tumour -
# - <0.01; ## - <0.005; ### - <0.0005 by Mann Whitney U test.
Table 4 Median values for cytokines and chemokines in plasma from non-malignant patients versus plasma from
patients with gastric carcinomas
MEDIAN for non-malignant
(n = 18) (in pg/ml)
RANGE (in pg/ml) MEDIAN for tumours
(n = 58) (in pg/ml)
RANGE (in pg/ml)
CFD/Adipsin 71520.0 58000.8 - 77527.9 69236.4 27926.9 - 95255.7
CXCL5/ENA-78 1100.6 0 - 7203.2 1702.8 0 - 11588.5
EpCAM 1789.8 0 - 13627.3 3527.1 0 - 35009.2
IGFBP-3 119467.1 20164.6 - 174498 110395.1 0 - 979359.6
IL-8/CXCL8 22.5 0 - 69.9 48.9* 0 - 396.3
CXCL10/IP-10 670.2 0 - 3328.9 931.1 0 - 5158.9
CXCL9/MIG 6069.2 0 - 18739.7 7561.8* 505-6 - 86999
CCL3/MIP-1a 1464.8 0 - 10602.2 2335.1* 0 - 32199
CCL4/MIP-1b 43.0 0 - 440.1 127.9 0 - 2138.5
CCL15/MIP-1δ 6628.8 1237.8 - 13178.1 5577.9 696.3 - 11054.4
CCL20/MIP-3a 139.9 0 - 1994.1 654.6# 0 - 12013.1
MMP-3 10966.2 3891.2 - 38928.9 13680.1 1358.7 - 80588.8
SPP1/OPN 4621.5 0 - 20518.1 8680.5 0 - 110373.2
PDGF R-B 1391.5 0 - 5461.8 2300.5* 0 - 34754.4
TIMP-1 31048.9 15603.8 - 220729.6 98054.6# 6252.5 - 463941
# - p value < 0.01; * - p value < 0.05 by Mann Whitney U test.
Rajkumar et al. Cancer Cell International 2010, 10:45
http://www.cancerci.com/content/10/1/45
Page 8 of 12
suggesting that they could be involved in the later stages
of gastric tumorigenesis. EpCAM is expressed by most
epithelial cell membranes and in gastrointestinal carci-
nomas. It has been shown to be overexpressed in gastric
carcinomas and when downregulated by siRNA, it leads
to decrease in cell proliferation, cell cycle arrest and
suppressed tumour formation in nude mice [43]. IL8 is
a potent pro-angiogenic and inflammatory chemokine
[44] and has been found to play a role in the inflamma-
tory response to H.pylori [45]. It has also been shown to
be involved in the invasiveness and angiogenesis of sev-
eral cancers including pancreatic cancer [46]. Of the
three related Macrophage inflammatory proteins (CCL3/
MIP - 1a, CCL4/MIP-1b and CCL15/MIP-1δ), CCL4/
MIP-1b was the most differentially expressed. This beta-
chemokine has been reported to be highly expressed in
diffuse type gastric cancers [47]. Inspite of the produc-
tion of these MIP proteins, the immune response to the
tumours is not effective probably due to functional
defects in the effector cells [48]. Chung et al (1992) [49]
reported the presence of PDGFR-B mRNA and protein
in the gastric tumours (using in situ hybridization and
IHC) but not in the adjacent non-malignant mucosa,
which is similar to our data.
We had chosen a large number of potentially secreted
proteins for our validation of the microarray data using
Taqman Real Time PCR (TLDA assay). Subsequently we
evaluated 15 proteins which are secreted, for validation
using the Quantibody protein array, both in gastric tis-
sues and in the plasma. The Median values and the
range of the 15 proteins in the plasma are given in
Table 4. CCL20/MIP-3a, TIMP1, IL8, PDGFR-B, CCL3/
MIP-1a and CXCL9/MIG were significantly elevated in
the plasma from the gastric cancer patients compared to
the plasma from individuals with no visible upper gas-
tro-intestinal pathology or those with benign lesions in
stomach. As in our study, TIMP1 levels have been
found to be elevated in gastric cancer patients compared
Figure 2 Pre (1) and Post-operative (2) plasma levels of the cytokines/chemokines/growth factors in gastric cancers (n = 8). The plasma
levels were measured using the Quantibody array, which uses the principle of sandwich ELISA in a multiplex format. The details for the
estimation of the levels are provided in the Methods section.
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to healthy controls [50,51]. CXCL5 levels were found to
be higher in late stage gastric cancer patients compared
to levels in patients with benign conditions [37].
The pre- and post-operative paired plasma samples
from gastric cancer patients who underwent radical sur-
gery showed concordant drop for most of the proteins
studied, except TIMP1, MIP-1δ and Adipsin. TIMP1
levels are known to be elevated following tissue injury.
TIMP1 levels have been found to be elevated in the
immediate post-operative period after curative resection
for colo-rectal cancers and it took between 28 - 60 days
to fall below the pre-operative levels [52]. Parsons et al.,
(2004) [53] have shown TIMP1 to be involved in
decreased degradation of extracellular matrix (ECM) by
blocking matrix metalloproteinase activity and enhanced
survival of hepatic stellate cells which are a major
source of ECM, leading to fibrosis in liver following che-
mical injury. CCL15/MIP-1δ has been shown to be
expressed constitutively in the intestinal epithelial cells
and play a role in chronic inflammatory pathologies of
the intestine such as Crohn’s disease and ulcerative coli-
tis [54]. It is not clear whether its level could be elevated
following surgery. This should be borne in mind if these
markers are planned to be evaluated as biomarkers for
either diagnosis or prognosis or follow-up.
In conclusion, our study has identified several genes
differentially expressed in gastric cancers, some for the
first time. Some of these have been confirmed at the
protein level, as well. In addition, we have shown some
of the proteins (CCL20/MIP-3a, TIMP1, IL8, PDGFR-B,
CCL3/MIP-1a and CXCL9/MIG) to be detected at a
higher level in the plasma from gastric cancer patients
than in patients with non-malignant gastric conditions
or with normal gastric mucosa. These will need to be
evaluated further for their potential as diagnostic bio-
markers in gastric cancers. A larger number of patients
and a longer duration of follow-up will be required to
obtain meaningful prognostic information particularly
with regard to survival.
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